“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

This study could potentially impact the stock performance of Regeneron Pharmaceuticals and Sanofi, as positive results may enhance investor sentiment and market valuation. The study’s focus on COPD, a ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Infants and young children with atopic dermatitis experienced improvements in signs and symptoms with dupilumab treatment regardless of other type 2 comorbidities, according to a study published ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

Dupilumab provides effective therapy for those who have failed other modalities, but it should not be considered first-line therapy for a number of reasons. First, it is costly.

Serious adverse events remained rare and skin remained largely clear in adolescents treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a phase 3 ...

Dermatology > General Dermatology Dupilumab Gets First FDA-Approved Indication for Prurigo Nodularis — Significant improvement in itch and nodules at 24 weeks seen in two randomized trials by ...

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine, 2021; 385 (24): 2230 DOI: 10.1056/NEJMoa2106567 ...

Dupilumab was added as an active comparator in the trial because its efficacy has been shown in this population and it was previously evaluated in a similarly designed proof-of-concept study. 6,7 ...